Showing 1681-1690 of 19301 results for "".
Advancing Pediatric MS Care: Insights from AAN 2026
https://reachmd.com/programs/neurofrontiers/pediatric-ms-aan-2026/54250/At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaEvaluating Eyelid Wipes for Dry Eye Disease: Clinical Trial Insights
https://reachmd.com/programs/eye-on-ocular-health/evaluating-eyelid-wipes-for-dry-eye-disease-clinical-trial-insights/37276/A recent study presented at the 2025 American Academy of Ophthalmology Annual Meeting evaluated a novel treatment option for dry eye disease: a TRPM8 agonist delivered via an eyelid wipe. Hear Dr. Houman D. Hemmati walk through the study's design, its findings on safety and efficacy, and the next stISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-and-dr-zirwas-discuss-itchy-patient/27065/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with Matthew Zirwas, MD, about Dr. Zirwas’s lecture on the itchy patient and the latest solutions for itch at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.The Impact of Advocacy on Healthcare
https://reachmd.com/programs/project-oncology/the-impact-of-advocacy-on-healthcare/24502/Why is advocacy important to the healthcare field? Tune in.Obesity and Asthma: Intersecting Pathways and Real-World Impacts
https://reachmd.com/programs/clinicians-roundtable/obesity-asthma-poor-disease-control/54181/Emerging evidence highlights a complex, bidirectional relationship between obesity and asthma, driven by shared genetics, epigenetic influences, environmental exposures, and metabolic dysfunction. Learn more with Dr. Anne Dixon, who’s a pulmonologist, professor, and the E. L. Amidon Chair of the DepBehind the Breakout: Acne as a Meaningful Side Effect of JAK Inhibitors for IBD
https://reachmd.com/programs/Audioabstracts/jak-inhibitors-acne-side-effect-ibd/49088/As JAK inhibitors become more widely used in treating inflammatory bowel disease (IBD), a new challenge is emerging: acne. That’s why Ryan Quigley spotlights the largest international cohort study to date examining JAK inhibitor-associated acne across more than 2,000 patients. Tune in to learn how fAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
https://reachmd.com/programs/neurofrontiers/program-name/36465/Over the past two decades, Alzheimer’s diagnosis has transformed from uncertain, exclusion-based methods to more accurate detection of disease pathology. With the advent of amyloid PET tracers, cerebrospinal fluid and plasma biomarkers like p-tau 217, and the promise of AI-driven imaging analysis, cThe Far-Reaching Impacts of Psoriasis: Understanding and Mitigating Risks
https://reachmd.com/programs/dermconsult/the-far-reaching-impacts-of-psoriasis-understanding-and-mitigating-risks/32452/Hear how psoriasis can impact a patient’s health beyond their skin and how to best support them to improve outcomes and minimize risks.Genetics in Psoriasis: Impacts on Risk, Comorbidities, and Care
https://reachmd.com/programs/frontlines-psoriasis/genetics-in-psoriasis-impacts-on-risk-comorbidities-and-care/32435/Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumOne Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
https://reachmd.com/programs/project-oncology/one-year-or-two-dante-trial-explores-immunotherapy-duration-in-metastatic-melanoma/33002/The DANTE phase III trial investigated if stopping anti–PD-1 therapy at one year yields comparable outcomes to longer treatment in metastatic melanoma. Read more about the findings and their potential clinical implications.